Moderna, Inc. MRNA
198.88
4.06
2.08%
as of 25 Sep
- Market cap
- $78.8B
- P/E
- 0.0×
Follow MRNA
Indexes
indicate stock being part of an index
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(29.32%) | (28.87%) | (36.56%) | (39.00%) | |
| (22.31%) | (21.31%) | (26.41%) | (27.43%) | ||
ROIC |
(44.61%) | (55.51%) | (76.00%) | (93.47%) | |
Return on Tangible Assets |
(44.24%) | (42.18%) | (58.49%) | (59.01%) | |
Average Days of Receivables |
171.05 | 34.55 | 11.65 | 2.79 | |
Free Cash Flow per Share |
(6.83) | (5.33) | (4.06) | (3.13) | |
Free Cash Flow |
(2,663.00) | (2,075.00) | (1,603.00) | (1,244.00) | |
Capital Expenditures |
(685.00) | (202.00) | (137.00) | (171.00) | |
Piotroski F-Score |
2.00 | 3.00 | 1.00 | 1.00 | |
| Other line items | |||||
Cash ROIC |
(14.27%) | (12.44%) | (11.09%) | (8.59%) | |
Accounts Receivable Turnover |
1.71 | 7.17 | 29.87 | 84.08 | |
Accounts Payable Turnover |
3.61 | 2.40 | 8.96 | 9.98 | |
Inventory Turnover |
3.10 | 6.43 | 12.65 | 6.57 | |
Average Days of Payables |
84.38 | 133.30 | 33.91 | 35.71 | |
Days of Inventory on Hand |
104.92 | 64.34 | 30.75 | 59.87 | |
Tax Rate |
(0.01) | 0.02 | 0.02 | 0.02 | |
Research and Development Expense of Revenue |
155.87% | 161.11% | 131.46% | 129.08% | |
Selling, General and Administrative Expense of Revenue |
47.54% | 52.37% | 44.00% | 43.31% | |
Share Based Compensation of Revenue |
21.24% | 24.85% | 21.21% | 20.74% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.63 | 0.66 | 0.46 | 0.34 | |
Depreciation/Fixed assets |
0.06 | 0.07 | 0.08 | 0.09 | |
Capex/Depreciation |
(5.07) | (1.36) | (0.78) | (0.90) | |
Revenue per Share |
5.72 | 5.00 | 5.63 | 5.60 | |
Operating CF per Share |
(5.07) | (4.81) | (3.71) | (2.70) | |
Capex per Share |
(1.76) | (0.52) | (0.35) | (0.43) | |
Capex to Sales |
0.31 | 0.10 | 0.06 | 0.08 | |
Net Profit Margin |
(139.61%) | (145.16%) | (143.55%) | (141.43%) |
Columns are period end dates